Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India
A PHASE 4, RANDOMIZED, OPEN-LABEL TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13- VALENT PNEUMOCOCCAL CONJUGATE VACCINE FORMULATED IN MULTIDOSE VIALS WHEN GIVEN WITH ROUTINE PEDIATRIC VACCINES IN HEALTHY INFANTS IN INDIA
Sponsor: Pfizer
This PHASE4 trial investigates Vaccines and is currently completed. Pfizer leads this study, which shows 11 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Mar 2020 — Oct 2020 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
May 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE4
-
Mar 2019 — May 2019 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Mar 2019 [monthly]
Recruiting PHASE4
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE4
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
May 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .